Serge Saxonov Sells 5,092 Shares of 10x Genomics, Inc. (NASDAQ:TXG) Stock

10x Genomics, Inc. (NASDAQ:TXG) CEO Serge Saxonov sold 5,092 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $56,368.44. Following the completion of the sale, the chief executive officer now directly owns 879,482 shares of the company’s stock, valued at approximately $9,735,865.74. The trade was a 0.58 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

10x Genomics Stock Up 4.9 %

NASDAQ TXG traded up $0.54 on Wednesday, reaching $11.65. The stock had a trading volume of 3,013,689 shares, compared to its average volume of 2,633,405. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of -7.66 and a beta of 1.85. 10x Genomics, Inc. has a 12-month low of $10.63 and a 12-month high of $48.42. The stock has a fifty day moving average price of $14.16 and a two-hundred day moving average price of $16.95.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Sell-side analysts forecast that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Canaccord Genuity Group lowered their target price on shares of 10x Genomics from $20.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Leerink Partnrs lowered shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 13th. Morgan Stanley lowered their target price on 10x Genomics from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Stifel Nicolaus cut their price objective on 10x Genomics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Finally, The Goldman Sachs Group decreased their price target on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a research note on Wednesday, October 30th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, 10x Genomics currently has a consensus rating of “Hold” and a consensus target price of $20.57.

Institutional Trading of 10x Genomics

Hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. grew its holdings in 10x Genomics by 355.0% in the third quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company’s stock valued at $8,027,000 after purchasing an additional 277,355 shares during the last quarter. Entropy Technologies LP raised its position in shares of 10x Genomics by 285.6% in the 4th quarter. Entropy Technologies LP now owns 37,595 shares of the company’s stock worth $540,000 after buying an additional 27,844 shares during the period. Geode Capital Management LLC lifted its stake in shares of 10x Genomics by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company’s stock valued at $41,009,000 after purchasing an additional 42,777 shares in the last quarter. SG Americas Securities LLC grew its stake in 10x Genomics by 209.8% during the fourth quarter. SG Americas Securities LLC now owns 73,046 shares of the company’s stock worth $1,049,000 after buying an additional 49,468 shares during the period. Finally, Point72 Asset Management L.P. acquired a new stake in 10x Genomics in the 3rd quarter valued at $27,778,000. 84.68% of the stock is owned by institutional investors and hedge funds.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.